Ovarian Cancer Clinical Trials


Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Condition:   Ovarian Cancer
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: Avelumab;   Drug: Avelumab
Sponsor:   Pfizer
Recruiting - verified July 2017

Learn More

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Conditions:   Non-Small Cell Lung Cancer;   Nonsmall Cell Lung Cancer;   Breast Cancer;   Cancer of Breast;   Cancer of the Breast;   Gastroesophageal Cancer;   Pancreatic Cancer;   Cancer of the Pancreas;   Colorectal Cancer;   Colorectal Carcinoma;   Renal Cancer;   Kidney Cancer;   Cancer of the Kidney;   Cancer of Kidney;   Ovarian Cancer;   Ovary Cancer;   Cancer of the Ovary;   Cancer of Ovary
Intervention:   Drug: MEDI4736
Sponsor:   Washington University School of Medicine
Recruiting - verified July 2017

Learn More

Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer

Conditions:   Triple Negative Breast Cancer;   Ovarian Cancer;   Breast Cancer;   Metastatic Breast Cancer;   Advanced Breast Cancer;   Stage IV Breast Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions:   Drug: niraparib;   Biological: pembrolizumab
Sponsors:   Tesaro, Inc.;   Merck Sharp & Dohme Corp.
Recruiting - verified August 2016

Learn More

PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Drug: IMGN853;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Topotecan
Sponsors:   ImmunoGen, Inc.;   Gynecologic Oncology Group
Recruiting - verified July 2017

Learn More

Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Ovarian Serous Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Drug: ATR Kinase Inhibitor VX-970;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More


A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Hodgkin Lymphoma or Other Solid Tumors

Conditions:   MELANOMA;   SCHNC;   OVCA;   SARCOMA;   HODGKIN LYMPHOMA;   OTHER SOLID TUMORS
Interventions:   Drug: PF-06801591;   Drug: PF-06801591
Sponsor:   Pfizer
Recruiting - verified July 2017

Learn More

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Conditions:   Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention:   Drug: Entrectinib
Sponsor:   Ignyta, Inc.
Recruiting - verified July 2017

Learn More

Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: SC-003
Sponsor:   Stemcentrx
Recruiting - verified July 2017

Learn More

A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services

Conditions:   Breast Cancer;   Ovarian Cancer;   Colorectal Cancer
Interventions:   Behavioral: Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site;   Behavioral: Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site;   Behavioral: Patient receives written information on how to find genetic services in their area
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified July 2017

Learn More

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

The Canadian/US Integrative Oncology Study

Conditions:   Breast Neoplasms;   Colorectal Neoplasms;   Pancreatic Neoplasms;   Ovarian Neoplasms
Intervention:  
Sponsors:   The Canadian College of Naturopathic Medicine;   Bastyr University;   Lotte & John Hecht Memorial Foundation
Recruiting - verified July 2016

Learn More

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
Interventions:   Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   BRCA Rearrangement;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Undifferentiated Carcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Tumor;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Tumor;   Ovarian Transitional Cell Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions:   Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment
Sponsors:   National Cancer Institute (NCI);   AstraZeneca
Recruiting - verified June 2017

Learn More

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Conditions:   Squamous Cell Carcinoma of the Head and Neck (SCCHN);   Ovarian Carcinoma;   Colorectal Cancer (CRC);   Renal Cell Carcinoma (RCC) (Phase ll Only);   Glioblastoma (GBM) (Phase ll Only)
Intervention:   Drug: Combination of varlilumab and nivolumab
Sponsors:   Celldex Therapeutics;   Bristol-Myers Squibb
Recruiting - verified July 2017

Learn More

46-60 of 69
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.